Cost-effectiveness of icosapent ethyl for primary and secondary cardiovascular prevention in the UK

Abstract Background Treatment with icosapent ethyl reduces the risk of major adverse cardiovascular events by 25% in patients hypertriglyceridemia compared to placebo as demonstrated The Reduction Cardiovascular Events Icosapent Ethyl-Intervention Trial (REDUCE-IT). Objective To assess cost-effectiveness ethyl, purified eicosapentaenoic acid ester, combination statins statin monotherapy for primary and secondary prevention from perspective England's National Health Service (NHS). Methods A Markov model simulated progression diseases acute events, including myocardial infarction, stroke, angina, coronary revascularization, dyslipidaemia patients. was populated outcome data derived REDUCE-IT trial. Cost utility were extracted peer-reviewed literature. incremental ratio (ICER) is reported per quality-adjusted life year (QALY) gained 2021 Great Britain Pounds (£). Univariate, scenario, willingness-to-pay, probabilistic sensitivity analyses conducted robustness results. Results For prevention, increased QALYs 0.79 costs £15,421 (ICER: 19,485 £/QALY). omega-3 fatty acid, extended 0.98 at £12,981 13,285 At NHS' willingness-to-pay threshold 25,000 £/QALY, there 98% 100% probability cost-effective respectively. remained robust under univariate, analyses. Conclusion an annual price £2,064 UK. Funding Acknowledgement Type funding sources: None.